A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Tracy Murray StewartDaniel Von HoffMichael FitzgeraldLaurence J MartonCarlos H Roberto BecerraThomas E BoydPaul R ConklingLawrence E GarboRobert M JotteDonald A RichardsDavid A SmithJoe J StephensonNicholas J VogelzangHillary H WuRobert A CaseroPublished in: Cancer chemotherapy and pharmacology (2020)
Results of this Phase Ib trial indicate that PG-11047 can be safely administered to patients in combination with bevacizumab, erlotinib, cisplatin, and 5-FU on the once weekly dosing schedule described and may provide therapeutic benefit. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- advanced non small cell lung cancer
- epidermal growth factor receptor
- chronic kidney disease
- prognostic factors
- clinical trial
- study protocol
- peritoneal dialysis
- diffuse large b cell lymphoma
- metastatic colorectal cancer
- open label
- squamous cell carcinoma
- phase iii
- phase ii
- double blind
- patient reported
- simultaneous determination
- placebo controlled